NDAORALTABLET
Approved
May 2014
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
3/8 — Basic
Drug data last refreshed 3h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZONTIVITY (vorapaxar sulfate) is an oral small-molecule protease-activated receptor-1 (PAR-1) antagonist approved in 2014 for reducing thrombotic cardiovascular events in patients with stable coronary artery disease or peripheral artery disease. It works by inhibiting platelet aggregation through a novel mechanism distinct from traditional antiplatelet agents. The drug is indicated for patients with established atherosclerotic disease seeking additional antithrombotic benefit.
$0.051MPart D
LOE Approaching1.2 years to LOEVery limited commercial footprint with minimal Part D utilization signals a niche, declining franchise requiring specialized expertise rather than large team expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
Worked on ZONTIVITY at Passkey Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.